@proteinqure
1 post audited · 1 claims analysed
Science evidence grade
Based on 1 claim across 1 audit
1
Supported
100%
0
Overstated
0%
0
Misleading
0%
0
No Evidence
0%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @proteinqure claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
100%
1 claim
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
0%
0 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(1 post)
“Peptide-drug conjugates (PDCs) mark a significant leap forward in developing therapies that are both highly targeted and exceptionally effective. A PDC is composed of three essential components: peptide (dark blue), linker and payload (bright yellow).”
The claim that peptide-drug conjugates (PDCs) are highly targeted and exceptionally effective is supported by current scientific literature. Two recent peer-reviewed reviews (2024-2025) explicitly characterize PDCs and related antibody-drug conjugates (ADCs) as delivering improved efficacy with reduced off-target toxicity, and multiple clinical trials demonstrate ongoing Phase 1-2 investigation of these therapies. The evidence tier is moderate-to-strong: based on mechanistic reviews, regulatory approvals (15 ADCs approved for clinical use), and active human trials—though individual PDC compounds themselves would require separate efficacy validation.
Audit another post from @proteinqure
Paste their Instagram link to add a new audit